Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Jump to: 2018 | 2010
Number of items: 2.

2018

Hillmen, Peter, Kater, Arnon P., Seymour, John Francis, Langerak, Anton W., Eichhorst, Barbara, Owen, Carolyn, Assouline, Sarit E., Janssens, Ann, Marlton, Paula, Badoux, Xavier C., Mous, Rogier, Chyla, Brenda, Humerickhouse, Rod, Boyer, Michelle, Humphrey, Kathryn, Jiang, Yanwen, Punnoose, Elizabeth, Wang, Jue, Wu, Qun Jenny and Mobasher, Mehrdad (2018). High, durable minimal residual disease negativity (MRD-) with venetoclax plus rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study. J. Clin. Oncol., 36 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

2010

Freedman, Arnold S., Kuruvilla, John, Assouline, Sarit E., Engert, Andreas, Heo, DaeSeog, Solal-Celigny, Philippe, Corradini, Paolo, Verhoef, Gregor, Fanale, Michelle A., Bendiske, Jennifer, Ewald, Brett, Dey, Jyotirmoy, Baeck, Johan and Younes, Anas (2010). Clinical Activity of Lucatumumab (HCD122) In Patients (pts) with Relapsed/Refractory Hodgkin or Non-Hodgkin Lymphoma Treated In a Phase Ia/II Clinical Trial (NCT00670592). Blood, 116 (21). S. 129 - 130. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

This list was generated on Fri Mar 29 15:22:13 2024 CET.